Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Published byMoses Brian Nash Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured."— Presentation transcript:

1 Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue.
Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. (A) Immunostaining showed that irisin was detected in the mouse lung tissue after IR injury with irisin treatment but not in sham-operated animals (scale bars, 50 μm). (B) Lung tissue sections were immunostained for irisin (green) and AT1a (red, alveolar type I epithelial cell marker) (scale bars, 20 μm). (C) The extent of reactive oxygen species (ROS) production in mouse lung tissue was determined by dihydroethidium staining (*P < 0.05 versus sham group and #P < 0.05 versus IR group; n = 5; scale bars, 100 μm). (D) Assessment of cytochrome c (cyc c) in mitochondria and cytosol derived from lung tissue subjected to IR (*P < 0.05 versus sham and #P < 0.05 versus IR; n = 4). COX IV, cyclooxygenase IV; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (E) Caspase 9 activation in lung tissue subjected to IR (*P < 0.05 versus sham and #P < 0.05 versus IR; n = 4). Ken Chen et al., Sci Transl Med 2017;9:eaao6298 Published by AAAS

Download ppt "Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured."

Similar presentations

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Fig. 7. Downstream effects of α-synuclein on mitochondria.

Fig. 7. Downstream effects of α-synuclein on mitochondria.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Bone Marrow-Derived Mesenchymal Stem Cells Expressing Thioredoxin 1 Attenuate Bleomycin-Induced Skin Fibrosis and Oxidative Stress in Scleroderma  Miao.

Bone Marrow-Derived Mesenchymal Stem Cells Expressing Thioredoxin 1 Attenuate Bleomycin-Induced Skin Fibrosis and Oxidative Stress in Scleroderma  Miao.
Fig. 3. Features of PH in KRasLA2 transgenic mice.

Fig. 3. Features of PH in KRasLA2 transgenic mice.
Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.

Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 4. Characterization of human liver seed graft morphology.

Fig. 4. Characterization of human liver seed graft morphology.
Fig. 4 Bone tissue formation within the Ti-mesh channels.

Fig. 4 Bone tissue formation within the Ti-mesh channels.
Representative images of immunohistochemical staining of discoidin domain receptor (DDR)2 in interstitial lung disease (ILD) other than idiopathic pulmonary.

Representative images of immunohistochemical staining of discoidin domain receptor (DDR)2 in interstitial lung disease (ILD) other than idiopathic pulmonary.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Similar presentations

Ads by Google